Aclaris Therapeutics: Latest News, Top Stories & Analysis - Page 2 of 2

Aclaris Therapeutics Announces Promising Phase 2b Results for ATI-1777, Boosting Investor Confidence

January 12, 2024January 11, 2024 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has released promising top-line results from its Phase 2b study of ATI-1777, a topical “soft” JAK 1/3 inhibitor developed for treating mild …

Public Companies

Aclaris Therapeutics Advances ATI-1777 into Phase 2b Trial, Plans Workforce Reduction to Preserve Capital

December 23, 2023December 20, 2023 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is making strategic moves, announcing several updates this week including promising trial results, a shift in drug development focus, and a significant …

Products and Services

Aclaris Therapeutics and Sun Pharma Sign Exclusive Patent License Agreement for Alopecia Treatment

December 7, 2023December 6, 2023 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc., a Pennsylvania-based biopharmaceutical company, announced this week that it has entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, Inc. (Sun Pharma). …

Products and Services / Research

Aclaris Therapeutics Halts Development of Rheumatoid Arthritis Drug After Phase 2b Study Misses Primary Endpoint

November 16, 2023November 14, 2023 - by Timothy Alexander

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced disappointing top-line results from a Phase 2b study of zunsemetinib (ATI-450) in patients with moderate to severe rheumatoid arthritis …

Finance

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results, Provides a Corporate Update

November 8, 2023November 7, 2023 - by MyChesCo

WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) this week announced its financial results for the third quarter of 2023 and provided a corporate update.